Summary of IIPR Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $69 million, a 3.5% increase from Q4 2025, driven by payments from PharmaCann and Gold Flora settlements.

Adjusted Funds from Operations (AFFO): $53.4 million, or $1.88 per share, consistent with the previous quarter.

Liquidity: Approximately $177 million, including $89 million in cash and $87.5 million available under revolving credit facilities.

Debt Metrics: Debt service coverage ratio over 11x and net debt to adjusted EBITDA of 1.1x, indicating strong credit metrics.

2Strategic Updates and Business Highlights

Regulatory Developments: The rescheduling of cannabis from Schedule I to Schedule III is seen as a significant milestone, potentially improving operator economics and access to capital.

Leasing Activity: New leases signed for 389,000 square feet across five properties; progress made in stabilizing the portfolio, particularly with former PharmaCann and Gold Flora assets.

IQHQ Investment: Continued commitment to IQHQ with $175 million funded out of a $270 million commitment, viewed as a strategic opportunity in the life sciences sector.

3Forward Guidance and Outlook

The company is focused on completing refinancing of unsecured debt and anticipates growth opportunities in the cannabis sector as regulatory clarity improves.

Management is optimistic about the potential for increased capital inflow and expansion opportunities following the regulatory changes, particularly in medical cannabis.

4Bad News, Challenges, or Points of Concern

Macroeconomic Headwinds: Persistent inflation and elevated interest rates continue to pose challenges for the operating environment.

Tenant Defaults: Ongoing issues with certain tenants, notably the need for retenanting properties previously leased to PharmaCann and Gold Flora, although progress is being made.

Regulatory Uncertainty: While the rescheduling is a positive step, there remains uncertainty regarding the full implications for adult-use cannabis and interstate commerce.

5Notable Q&A Insights

Leasing Commencement: Management indicated that new leases may take time to commence due to regulatory approvals and potential free rent periods, with expectations for contributions to revenue varying between 2026 and 2027.

280E Tax Relief: The potential for retroactive tax relief for medical operators under Schedule III was discussed, with management believing it would improve tenant economics but not eliminate all credit risks.

Future Investments: Management expressed confidence in pursuing additional growth opportunities in cannabis and life sciences post-debt refinancing, with a focus on medical cannabis markets in states like Texas and Georgia. Overall, IIPR's Q1 2026 results reflect a solid start to the year amid regulatory advancements and strategic leasing efforts, though challenges remain in the broader economic landscape and tenant performance.